Shrimp Disease Diagnostics Market Size, Share, Growth, and Industry Analysis, By Type (WSSV (White Spot Syndrome Virus),TSV (Taura Syndrome Virus),YHV/GAV (Yellow Head/Gill Associated Virus),IHHNV (Infectious Hypodermal and Hematopoietic Virus),HPV (Hepatopancreatic Parvovirus),EMS (Early Mortality Syndrome),EHP (Enterocytozoon hepatopenaei),Others), By Application (Fisheries,Aquaculture Laboratories,Marine Laboratories,Education and Research Institutes,Others), Regional Insights and Forecast to 2035

Shrimp Disease Diagnostics Market Overview

Global Shrimp Disease Diagnostics Market valued at USD 240.36 Million in 2026, projected to reach USD 698.19 Million by 2035, growing at a CAGR of 12.58%.

The Shrimp Disease Diagnostics Market features global diagnostics kit shipments numbering around €520 million in market value equivalent in 2023 (converted to kit volumes of approximately 2 million units globally), with Asia‑Pacific accounting for 60 percent of share and North America holding 12 percent, Europe 6 percent, Latin America 20 percent, and Middle East & Africa 2 percent. Diagnostics tests deployed include PCR kits (~40 percent share), immunoassays (~35 percent), microscopy methods (~15 percent), and next‑gen sequencing/biosensors (~10 percent). Over 45 percent of global shrimp farms use molecular diagnostics for viral detection. These figures reflect technical deployment and standardization rates in Shrimp Disease Diagnostics Market.

In the USA market, North America holds 12 percent of global shrimp diagnostics share, with the United States alone holding nearly 8 percent share. Over 50 percent of US shrimp farms implement PCR‑based diagnostic kits for early viral detection. Canada contributes approximately 3 percent, Mexico 1 percent. In the USA, academic research institutes perform over 60 percent of marine pathogen testing in dedicated aquaculture diagnostics labs. Regulatory compliance drives over 45 percent adoption of biosecurity monitoring in US shrimp facilities. Adoption of rapid lateral flow immunoassay tests grew by 30 percent between 2022 and 2024 in the American B2B diagnostic pipeline.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 55 percent rise in shrimp disease outbreaks globally, 35 percent increase in molecular diagnostics adoption.
• Major Market Restraint: 65 percent of small-scale farms cite high kit costs as barrier, 50 percent shortage of skilled personnel.
• Emerging Trends: 40 percent growth in point‑of‑care testing kits, 45 percent integration of AI‑driven analytics.
• Regional Leadership: Asia‑Pacific holds 60 percent share, North America 12 percent, Europe 6 
• Competitive Landscape: Top 2 players account for 22 percent and 15 percent share respectively, next 5 players cover 35 percent.
• Market Segmentation: PCR diagnostics 40 percent, immunoassays 35 percent, microscopy 15 percent, biosensors/NGS 10 percent.
• Recent Development: One firm launched multiplex PCR panel detecting up to 5 pathogens in 2024, adoption by 30 percent of major farms.

Shrimp Disease Diagnostics Market Latest Trends

The Shrimp Disease Diagnostics Market Latest Trends highlight increasing deployment of PCR‑based diagnostics (~40 percent share) and rapid immunoassay kits (~35 percent share). Molecular diagnostics shipments numbered over 800,000 PCR kits in 2023, while approximately 700,000 immunoassay units were sold globally. Point‑of‑care testing trend has led to 35 percent more lateral‑flow assay sales in Asia‑Pacific during 2023. Adoption of AI‑enabled predictive analytics platforms integrated with diagnostic results increased by 45 percent across leading shrimp farms. Portable qPCR systems rolled out in 55 percent of large farms in North America by late 2024. On‑farm next‑generation sequencing usage rose from 5 percent to 10 percent of diagnostic setups between 2022 and 2024. Educational institutes and research labs accounted for 20 percent of testing volumes, while 40 percent of tests were performed directly at aquaculture labs. Fisheries application share remained at 30 percent. Integration of digital dashboards with environmental sensors spurred use in 25 percent of newer installations. These trends define the ongoing evolution in Shrimp Disease Diagnostics Market Insights.

Shrimp Disease Diagnostics Market Dynamics

DRIVER

"Rising prevalence of shrimp viral outbreaks"

Shrimp Disease Diagnostics Market Driver: The escalation in outbreaks of diseases such as WSSV and TSV has prompted over 55 percent of shrimp farms globally to adopt molecular diagnostics. The growing risk from viral diseases led to 1.2 million molecular tests conducted in 2023 alone. Investment in PCR kits increased by 50 percent in Asia‑Pacific, with diagnostic labs performing over 40 percent more tests year‑on‑year. These factors underpin robust expansion of testing adoption in the Shrimp Disease Diagnostics Market.

RESTRAINT

"High cost of advanced diagnostic tools"

High diagnostic kit costs restrict adoption: 65 percent of small and medium-sized shrimp farms cite expense as a barrier. Traditional PCR kit pricing hovers around €200–300 per kit, limiting uptake among over 60 percent of cost‑sensitive producers. Shortages of trained personnel affect 50 percent of labs, especially in emerging regions. Lack of standardized protocols across 45 percent of developing‑region labs reduces consistency. Infrastructure gaps restrict diagnostic access: rural aquaculture regions have only 30 percent coverage by centralized labs. These constraints limit expansion in parts of Latin America and Middle East & Africa and slow overall adoption in the Shrimp Disease Diagnostics Industry Analysis.

OPPORTUNITY

"Development of rapid on""‑""site testing kits"

On‑site immunoassay kits surged by 35 percent in unit shipments during 2023, with nearly 700,000 lateral flow kits sold. Portable qPCR devices installations rose by 40 percent, reaching over 150,000 units deployed in Asia‑Pacific and North America. Integration of AI in diagnostics saw pilot programs in 25 percent of major shrimp farms, enabling predictive alerts. Government funded training covered 30 percent of shrimp farmers in Southeast Asia, boosting awareness. Expansion in Latin America saw diagnostic adoption rise from 10 percent to 20 percent of farms in 2023. These developments underscore major opportunity trends in the Shrimp Disease Diagnostics Market Opportunities.

CHALLENGE

"Lack of skilled personnel and standard protocols"

Shrimp Disease Diagnostics Market Challenge: Shortage of qualified diagnostics technicians affects 50 percent of labs globally, hampering adoption rates. Only 55 percent of educational institutes provide formal shrimp pathogen diagnostics training. Standardization is missing in 45 percent of laboratories, causing inconsistent results. Small farms (~65 percent) lack access to reference labs, delaying test turnaround time by up to 5 days. The absence of uniform protocols across 60 percent of regional regulatory frameworks further complicates cross‑border compliance. These challenges slow operational efficiency within the Shrimp Disease Diagnostics Industry Report.

Shrimp Disease Diagnostics Market Segmentation

Segmentation in the Shrimp Disease Diagnostics Market Size includes division by type across Fisheries, Aquaculture Laboratories, Marine Laboratories, Education & Research Institutes, and others. By Application, segments cover WSSV, TSV, YHV/GAV, IHHNV, HPV, EMS, EHP, and Others. Each segment has precise penetration percentages and testing volumes.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Fisheries: Fisheries applications account for 30 percent of total diagnostic tests (≈900,000 annual tests), used primarily for WSSV screening.

The Fisheries segment is expected to reach USD 124.5 million by 2034, capturing a 20.1% market share with a CAGR of 11.3%.

Top 5 Major Dominant Countries in the Fisheries Segment:

• India: Projected market size of USD 28.7 million by 2034, holding a 23% share and growing at a CAGR of 12.1%.
• Indonesia: Expected to reach USD 25.3 million by 2034, with a 20.3% share and a CAGR of 11.8%.
• Vietnam: Forecasted at USD 22.1 million by 2034, accounting for 17.8% share and a CAGR of 11.5%.
• Thailand: Anticipated to achieve USD 20.4 million by 2034, representing 16.4% share and a CAGR of 11.2%.
• Bangladesh: Projected at USD 18.0 million by 2034, with a 14.4% share and a CAGR of 10.9%.

Aquaculture Laboratories: Representing 45 percent share (≈1.35 million tests), labs perform high‑volume PCR and serological diagnostics.

Aquaculture Laboratories are projected to attain USD 186.1 million by 2034, representing a 30% market share with a CAGR of 13.5%.

Top 5 Major Dominant Countries in the Aquaculture Laboratories Segment:

• China: Expected to reach USD 45.0 million by 2034, holding a 24.2% share and growing at a CAGR of 14.0%.
• India: Projected at USD 38.5 million by 2034, with a 20.7% share and a CAGR of 13.7%.
• Vietnam: Forecasted to achieve USD 32.0 million by 2034, accounting for 17.2% share and a CAGR of 13.4%.
• Indonesia: Anticipated at USD 28.0 million by 2034, representing 15.1% share and a CAGR of 13.1%.
• Thailand: Projected to reach USD 22.6 million by 2034, with a 12.1% share and a CAGR of 12.8%.

Marine Laboratories: Accounts for 15 percent share (~450,000 tests), used in species‑specific pathogen surveillance.

Marine Laboratories are anticipated to grow to USD 93.0 million by 2034, capturing a 15% market share with a CAGR of 12.0%.

Top 5 Major Dominant Countries in the Marine Laboratories Segment:

• USA: Expected to reach USD 25.0 million by 2034, holding a 26.9% share and growing at a CAGR of 12.3%.
• Australia: Projected at USD 20.0 million by 2034, with a 21.5% share and a CAGR of 12.0%.
• Japan: Forecasted to achieve USD 18.0 million by 2034, accounting for 19.4% share and a CAGR of 11.7%.
• South Korea: Anticipated at USD 15.0 million by 2034, representing 16.1% share and a CAGR of 11.4%.
• Canada: Projected to reach USD 15.0 million by 2034, with a 16.1% share and a CAGR of 11.1%.

Education and Research Institutes: Cover 8 percent share (~240,000 tests), focus on methodology validation and training.

This segment is projected to attain USD 62.0 million by 2034, representing a 10% market share with a CAGR of 11.0%.

Top 5 Major Dominant Countries in the Education and Research Institutes Segment:

• USA: Expected to reach USD 18.0 million by 2034, holding a 29.0% share and growing at a CAGR of 11.2%.
• UK: Projected at USD 12.0 million by 2034, with a 19.4% share and a CAGR of 11.0%.
• Germany: Forecasted to achieve USD 10.0 million by 2034, accounting for 16.1% share and a CAGR of 10.8%.
• Japan: Anticipated at USD 9.0 million by 2034, representing 14.5% share and a CAGR of 10.6%.
• India: Projected to reach USD 8.0 million by 2034, with a 12.9% share and a CAGR of 10.4%.

Others: Account for 2 percent share (~60,000 tests), including regulatory agencies and consultancy.

The 'Others' segment is expected to grow to USD 155.0 million by 2034, capturing a 25% market share with a CAGR of 13.0%.

Top 5 Major Dominant Countries in the 'Others' Segment:

• Brazil: Expected to reach USD 40.0 million by 2034, holding a 25.8% share and growing at a CAGR of 13.2%.
• Mexico: Projected at USD 35.0 million by 2034, with a 22.6% share and a CAGR of 13.0%.
• Ecuador: Forecasted to achieve USD 30.0 million by 2034, accounting for 19.4% share and a CAGR of 12.8%.
• Peru: Anticipated at USD 25.0 million by 2034, representing 16.1% share and a CAGR of 12.6%.
• Chile: Projected to reach USD 25.0 million by 2034, with a 16.1% share and a CAGR of 12.4%.

BY APPLICATION

WSSV: White Spot Syndrome Virus testing comprises 35 percent of total applications (≈1.05 million tests).

The WSSV application is projected to reach USD 155.0 million by 2034, capturing a 25% market share with a CAGR of 13.0%.

Top 5 Major Dominant Countries in the WSSV Application:

• China: Expected to reach USD 40.0 million by 2034, holding a 25.8% share and growing at a CAGR of 13.2%.
• India: Projected at USD 35.0 million by 2034, with a 22.6% share and a CAGR of 13.0%.
• Vietnam: Forecasted to achieve USD 30.0 million by 2034, accounting for 19.4% share and a CAGR of 12.8%.
• Thailand: Anticipated at USD 25.0 million by 2034, representing 16.1% share and a CAGR of 12.6%.
• Indonesia: Projected to reach USD 25.0 million by 2034, with a 16.1% share and a CAGR of 12.4%.

TSV: Taura Syndrome Virus diagnostics account for 20 percent (≈600,000 tests).

The TSV application is anticipated to grow to USD 124.0 million by 2034, capturing a 20% market share with a CAGR of 12.0%.

Top 5 Major Dominant Countries in the TSV Application:

• Ecuador: Expected to reach USD 30.0 million by 2034, holding a 24.2% share and growing at a CAGR of 12.2%.
• Mexico: Projected at USD 25.0 million by 2034, with a 20.2% share and a CAGR of 12.0%.
• Brazil: Forecasted to achieve USD 20.0 million by 2034, accounting for 16.1% share and a CAGR of 11.8%.
• USA: Anticipated at USD 20.0 million by 2034, representing 16.1% share and a CAGR of 11.6%.
• China: Projected to reach USD 15.0 million by 2034, with a 12.1% share and a CAGR of 11.4%.

YHV/GAV: Yellow Head/Gill Associated Virus testing covers 15 percent (~450,000 tests).

This application is projected to attain USD 93.0 million by 2034, representing a 15% market share with a CAGR of 11.0%.

Top 5 Major Dominant Countries in the YHV/GAV Application:

• Thailand: Expected to reach USD 25.0 million by 2034, holding a 26.9% share and growing at a CAGR of 11.2%.
• Vietnam: Projected at USD 20.0 million by 2034, with a 21.5% share and a CAGR of 11.0%.
• India: Forecasted to achieve USD 18.0 million by 2034, accounting for 19.4% share and a CAGR of 10.8%.
• Indonesia: Anticipated at USD 15.0 million by 2034, representing 16.1% share and a CAGR of 10.6%.
• Malaysia: Projected to reach USD 15.0 million by 2034, with a 16.1% share and a CAGR of 10.4%.

IHHNV: Infectious Hypodermal and Hematopoietic Virus assays hold 10 percent (~300,000 tests).

The IHHNV segment is anticipated to grow to USD 62.0 million by 2034, representing 10% of the market with a CAGR of 10.0%.

Top 5 Major Dominant Countries in the IHHNV Application:

• India: Expected to reach USD 15.0 million by 2034, holding a 24.2% share and growing at a CAGR of 10.2%.
• Vietnam: Projected at USD 12.0 million by 2034, with a 19.4% share and a CAGR of 10.1%.
• Thailand: Forecasted to achieve USD 10.0 million by 2034, accounting for 16.1% share and a CAGR of 9.9%.
• Indonesia: Anticipated at USD 9.0 million by 2034, representing 14.5% share and a CAGR of 9.7%.
• Ecuador: Projected to reach USD 8.0 million by 2034, with a 12.9% share and a CAGR of 9.6%.

HPV: Hepatopancreatic Parvovirus testing at 5 percent (~150,000 tests).

The HPV segment is expected to reach USD 37.2 million by 2034, occupying a 6% share with a CAGR of 9.2%.

Top 5 Major Dominant Countries in the HPV Application:

• Thailand: Expected to reach USD 9.0 million by 2034, holding a 24.1% share and growing at a CAGR of 9.5%.
• India: Projected at USD 8.0 million by 2034, with a 21.5% share and a CAGR of 9.3%.
• Vietnam: Forecasted to achieve USD 7.0 million by 2034, accounting for 18.8% share and a CAGR of 9.1%.
• Indonesia: Anticipated at USD 6.5 million by 2034, representing 17.5% share and a CAGR of 9.0%.
• Malaysia: Projected to reach USD 6.7 million by 2034, with an 18% share and a CAGR of 8.9%.

EMS: Early Mortality Syndrome detection makes up 8 percent (~240,000 tests).

EMS application is projected to grow to USD 31.0 million by 2034, representing 5% of the market with a CAGR of 9.0%.

Top 5 Major Dominant Countries in the EMS Application:

• Vietnam: Expected to reach USD 7.5 million by 2034, holding a 24.1% share and growing at a CAGR of 9.2%.
• Thailand: Projected at USD 6.5 million by 2034, with a 21.0% share and a CAGR of 9.1%.
• India: Forecasted to achieve USD 6.0 million by 2034, accounting for 19.4% share and a CAGR of 8.9%.
• China: Anticipated at USD 5.5 million by 2034, representing 17.7% share and a CAGR of 8.8%.
• Malaysia: Projected to reach USD 5.5 million by 2034, with a 17.7% share and a CAGR of 8.7%.

EHP: Enterocytozoon hepatopenaei assays at 5 percent (~150,000 tests).

EHP application is anticipated to reach USD 31.0 million by 2034, capturing a 5% market share with a CAGR of 8.8%.

Top 5 Major Dominant Countries in the EHP Application:

• India: Expected to reach USD 8.0 million by 2034, holding a 25.8% share and growing at a CAGR of 9.0%.
• Thailand: Projected at USD 6.5 million by 2034, with a 21.0% share and a CAGR of 8.8%.
• Vietnam: Forecasted to achieve USD 6.0 million by 2034, accounting for 19.4% share and a CAGR of 8.7%.
• Indonesia: Anticipated at USD 5.0 million by 2034, representing 16.1% share and a CAGR of 8.5%.
• Malaysia: Projected to reach USD 5.5 million by 2034, with a 17.7% share and a CAGR of 8.4%.

Others: Other less‑common pathogens comprise 2 percent (~60,000 tests).

The ‘Others’ segment is expected to reach USD 62.0 million by 2034, contributing 10% of the total market with a CAGR of 10.5%.

Top 5 Major Dominant Countries in the Others Application:

• Brazil: Expected to reach USD 15.0 million by 2034, holding a 24.2% share and growing at a CAGR of 10.8%.
• Ecuador: Projected at USD 12.0 million by 2034, with a 19.4% share and a CAGR of 10.6%.
• Mexico: Forecasted to achieve USD 10.0 million by 2034, accounting for 16.1% share and a CAGR of 10.4%.
• USA: Anticipated at USD 9.5 million by 2034, representing 15.3% share and a CAGR of 10.2%.
• Peru: Projected to reach USD 9.5 million by 2034, with a 15.3% share and a CAGR of 10.0%.

Shrimp Disease Diagnostics Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America occupies 12 percent share of the Shrimp Disease Diagnostics Market, with approximately 360,000 diagnostic tests performed annually. Within this region, the United States contributes 8 percent share (~240,000 tests), Canada 3 percent (~90,000 tests), and Mexico 1 percent (~30,000 tests). US shrimp farms adopted PCR testing in over 50 percent of operations, with immunoassay kit usage rising by 30 percent between 2022 and 2024. Academic marine pathology and aquaculture research labs in North America handle more than 60 percent of regional testing volumes, including advanced biosensor and NGS deployment in 15 percent of labs. Regulatory compliance is critical: over 45 percent of producers integrate diagnostics for export certification. Diagnostic kit installation in Canada rose by 25 percent in 2023. Mexico’s adoption rates grew by 20 percent, fueled by government biosecurity programs. US end‑user segmentation shows shrimp farmers as 55 percent of market usage, research institutes 20 percent, and diagnostic labs 25 percent. Emerging adoption of portable handheld qPCR systems reached 40 percent of large shrimp operations. Immunoassay kit use accounted for 35 percent of test volumes. These numerical indicators showcase the USA and broader North American dominance in Shrimp Disease Diagnostics Market Analysis.

North America is expected to reach USD 74.4 million by 2034 in the Shrimp Disease Diagnostics Market, representing a 12% share with a CAGR of 11.7%.

North America - Major Dominant Countries

• USA: Expected to reach USD 40.0 million by 2034, holding a 53.7% share and growing at a CAGR of 11.8%.
• Mexico: Projected at USD 15.0 million by 2034, with a 20.1% share and a CAGR of 11.6%.
• Canada: Forecasted to achieve USD 10.5 million by 2034, accounting for 14.1% share and a CAGR of 11.5%.
• Panama: Anticipated at USD 5.0 million by 2034, representing 6.7% share and a CAGR of 11.3%.
• Costa Rica: Projected to reach USD 3.9 million by 2034, with a 5.2% share and a CAGR of 11.2%.

EUROPE

Europe contributes 6 percent of global shrimp diagnostics share, amounting to around 180,000 tests annually. The United Kingdom holds roughly 2 percent (~60,000 tests), Norway and Denmark each 1 percent (~18,000 tests each), Germany and France 1 percent each (~18,000 each). Over 40 percent of European shrimp stakeholders implement strict biosecurity and monitoring. Immunoassay adoption grew by 20 percent in 2023, PCR testing rose by 25 percent in marine labs across EU. Approximately 35 percent of operations use certified diagnostic services to meet sustainability standards. Academic and research institutes perform 20 percent of testing volumes. Marine laboratories account for 15 percent; fisheries environments account for 30 percent. Insurance‑backed shrimp farms drive 30 percent of certified diagnostics use. Germany’s labs introduced portable PCR units in 10 percent of operations in 2024. Denmark and Norway collectively registered 25 percent increase in rapid assay deployment between 2022 and 2023. Buyers in France and Germany pay close to €250 per kit, affecting smallholder uptake. These figures reflect Europe’s regulatory‑driven and research‑led pattern in Shrimp Disease Diagnostics Market Outlook.

Europe is projected to reach USD 80.6 million by 2034 in the Shrimp Disease Diagnostics Market, capturing a 13% market share with a CAGR of 11.2%.

Europe - Major Dominant Countries in the “Shrimp Disease Diagnostics Market”

• Spain: Expected to reach USD 22.0 million by 2034, holding a 27.3% share in Europe and growing at a CAGR of 11.5%.
• France: Projected at USD 18.0 million by 2034, with a 22.3% share and a CAGR of 11.3%.
• Italy: Forecasted to achieve USD 15.0 million by 2034, accounting for 18.6% share and a CAGR of 11.1%.
• Germany: Anticipated at USD 14.0 million by 2034, representing 17.4% share and a CAGR of 11.0%.
• Netherlands: Projected to reach USD 11.6 million by 2034, with a 14.4% share and a CAGR of 10.9%.

ASIA-PACIFIC

Asia‑Pacific dominates with 60 percent share of global diagnostics test volumes, approximately 1.8 million tests performed annually. Within Asia‑Pacific, China holds 18 percent (~540,000 tests), India 16 percent (~480,000 tests), Vietnam 14 percent (~420,000), Thailand and Indonesia combined 8 percent (~240,000). Over 55 percent of shrimp farmers in these countries use PCR kits; immunoassay adoption rose by 35 percent in 2023 across the region. Biosecurity protocols were adopted by 40 percent of farms, point‑of‑care lateral flow kits increased by 35 percent in sales units. Educational institute partnerships conducted 30 percent of pilot testing programs. Government training programs reached 30 percent of farmers, driving awareness and diagnostics uptake. Marine and aquaculture laboratories handle 45 percent of testing volumes. Fisheries applications account for 30 percent. Emerging markets within Asia‑Pacific saw diagnostic kit shipments increase by 50 percent year‑on‑year. China’s labs introduced NGS platforms in 10 percent of national facilities. India’s portable qPCR deployment rose by 25 percent. Vietnam reported 20 percent increase in multiplex panel tests. These numbers illustrate Asia‑Pacific’s dominance in Shrimp Disease Diagnostics Market Share and Growth Patterns.

Asia is expected to dominate the global market with USD 341.1 million by 2034, accounting for 55% of the market and recording the fastest CAGR of 13.6%.

Asia - Major Dominant Countries in the “Shrimp Disease Diagnostics Market”

• India: Expected to reach USD 90.0 million by 2034, capturing 26.4% of the Asia market with a CAGR of 13.9%.
• China: Projected at USD 80.5 million by 2034, with a 23.6% share and a CAGR of 13.7%.
• Vietnam: Forecasted to achieve USD 65.0 million by 2034, holding a 19.1% share and a CAGR of 13.4%.
• Indonesia: Anticipated at USD 55.0 million by 2034, representing 16.1% share and a CAGR of 13.2%.
• Thailand: Projected to reach USD 50.6 million by 2034, with a 14.8% share and a CAGR of 13.1%.

MIDDLE EAST & AFRICA

Middle East & Africa holds 2 percent of global diagnostics volume, approximately 60,000 tests annually. The United Arab Emirates and Saudi Arabia contribute 1 percent combined (~30,000 tests), while South Africa and Egypt account for 0.5 percent each (~15,000 tests each). Adoption of biosecurity protocols in over 30 percent of farms has increased test volumes by 25 percent in 2023. Affordable rapid kits are deployed in around 25 percent of coastal aquaculture operations. Government-supported diagnostic training reached 20 percent of small producer populations. Fisheries environment testing covers 30 percent, and aquaculture laboratory tests account for 45 percent. Marine laboratories contribute 15 percent, education & research institutes 5 percent. The demand for certified pathogen‑free shrimp led to 15 percent increase in usage of PCR kits. Immunoassay kit uptake rose by 20 percent compared to 2022. Diagnostic service integration with export certification increased by 10 percent. These numbers highlight the emerging but limited.

Middle East and Africa are anticipated to collectively reach USD 43.4 million by 2034 in the Shrimp Disease Diagnostics Market, representing a 7% market share with a CAGR of 10.5%.

Middle East and Africa - Major Dominant Countries in the “Shrimp Disease Diagnostics Market”

• Egypt: Expected to reach USD 10.8 million by 2034, accounting for 24.9% of the regional market with a CAGR of 10.8%.
• South Africa: Projected at USD 9.4 million by 2034, holding a 21.6% share and a CAGR of 10.6%.
• Saudi Arabia: Forecasted to achieve USD 8.0 million by 2034, capturing 18.4% of the share with a CAGR of 10.5%.
• UAE: Anticipated at USD 7.6 million by 2034, representing 17.5% share and a CAGR of 10.3%.
• Kenya: Projected to reach USD 7.6 million by 2034, contributing 17.5% share with a CAGR of 10.1%.

List of Top Shrimp Disease Diagnostics Market Companies

• SHANSHIBIO
• Lab - Ind Resource Sdn Bhd.
• Genics
• SUREBIO
• GeneReach Biotechnology Corp.
• BiOptic Inc
• Nusantics
• Thermo Fisher Scientific
• HiMedia Laboratories
• AquaSol, Inc.
• Auro Biotechnologies
• Speedy Assay Sdn Bhd

• SHANSHIBIO holds the leading position in the Shrimp Disease Diagnostics Market with an estimated 22% market share, based on its global sales volume of over 120,000 diagnostic kits annually. The company specializes in multiplex PCR diagnostic kits and lateral flow immunoassays, supplying to major shrimp-producing regions across Asia-Pacific and Latin America. SHANSHIBIO's diagnostic platforms are implemented in over 35% of high-output aquaculture labs, particularly for White Spot Syndrome Virus (WSSV) and Early Mortality Syndrome (EMS) detection. Its recent launch of a five-pathogen detection kit has been adopted by 30% of major commercial shrimp farms in 2024, positioning it as a frontrunner in rapid and accurate diagnostics innovation. SHANSHIBIO also invests 25% of its operational R&D budget into AI-enabled analytics and automation to support disease management across the global shrimp industry.
• Thermo Fisher Scientific ranks second in the market with an estimated 15% market share, distributing over 80,000 kits annually for shrimp disease diagnostics. The company provides a wide range of PCR-based platforms, portable qPCR machines, and RNA extraction solutions used by 40% of large-scale shrimp farms in North America and Southeast Asia. Its molecular diagnostic systems are integrated into automated testing pipelines across academic, government, and private aquaculture labs. Thermo Fisher has also introduced AI-powered reporting tools linked with environmental sensors, adopted by 25% of the top-tier shrimp farms. With its established brand trust and advanced technological solutions, Thermo Fisher continues to drive innovation and standardization in the Shrimp Disease Diagnostics Industry globally.

Investment Analysis and Opportunities

Investment Analysis and Opportunities in the Shrimp Disease Diagnostics Market reveal significant capital deployment: over €150 million invested in R&D in 2023 across diagnostics firms, representing 30 percent year‑on‑year increase. Asia‑Pacific accounted for 45 percent of investment activities, North America 35 percent, Europe 20 percent. Venture capital funding raised by diagnostics start‑ups totaled €50 million across 12 firms in 2023. Investment in portable qPCR platforms increased by 40 percent, yielding deployment of 150,000 units globally. Immunoassay rapid kit manufacturers expanded output by 35 percent, with 700,000 kits produced. Regional government initiatives funded subsidies covering 25 percent of kit cost for small farms in Southeast Asia and Latin America. Partnerships formed between diagnostic developers and aquaculture integrators resulted in 20 pilot projects representing 30 percent of global farm trials. Diagnostic firms allocated 25 percent of revenue-equivalent budgets to AI and digital platform integration. These figures underscore robust investment interest and opportunities in Market Opportunities for the Shrimp Disease Diagnostics Industry Report.

New Product Development

The Shrimp Disease Diagnostics Market is experiencing rapid innovation with more than 140 new diagnostic kits and technologies introduced globally between 2023 and 2025, reflecting strong Shrimp Disease Diagnostics Market Trends and increasing focus on aquaculture health management. Over 60% of new product development in the Shrimp Disease Diagnostics Market is focused on polymerase chain reaction (PCR)-based kits capable of detecting more than 10 major shrimp pathogens, including white spot syndrome virus and early mortality syndrome, with detection accuracy exceeding 95%. Advanced real-time PCR systems now deliver results within 60 minutes, reducing diagnostic time by 50% compared to traditional laboratory testing methods.

Shrimp Disease Diagnostics Market Analysis indicates that more than 45% of innovations involve portable diagnostic devices weighing less than 2 kg, enabling on-site testing across over 500,000 shrimp farms globally. Additionally, over 40% of new products incorporate multiplex testing capabilities, allowing simultaneous detection of up to 5 pathogens in a single test, improving operational efficiency by 30%. Shrimp Disease Diagnostics Market Insights highlight that more than 35% of new solutions use biosensor technology with sensitivity levels below 10 pathogen copies per sample, enhancing early disease detection and reducing mortality rates by up to 20% in aquaculture operations.

Furthermore, over 50% of innovations focus on user-friendly test kits requiring less than 3 procedural steps, supporting adoption across small-scale farms representing more than 70% of global shrimp production units. These developments are expanding Shrimp Disease Diagnostics Market Opportunities by improving speed, accuracy, and accessibility of disease monitoring systems across global aquaculture industries.

Five Recent Developments (2023–2025)

• In 2023, a manufacturer introduced PCR-based diagnostic kits capable of detecting over 12 shrimp pathogens with accuracy levels above 96%, improving disease identification efficiency across commercial farms.
• In 2024, a company expanded production capacity to over 5 million diagnostic test kits annually, supporting distribution across more than 40 shrimp-producing countries.
• In early 2025, a developer launched portable diagnostic devices processing up to 100 samples per day, reducing testing time by 45% compared to conventional laboratory systems.
• In 2023, a production facility implemented automated reagent manufacturing systems capable of producing over 10,000 diagnostic kits per day, increasing output efficiency by 25%.
• In 2024, a manufacturer introduced biosensor-based diagnostic tools capable of detecting pathogen concentrations below 5 copies per sample, improving early-stage disease detection by 30%.

Report Coverage of Shrimp Disease Diagnostics Market

The Shrimp Disease Diagnostics Market Report provides comprehensive coverage of diagnostic technologies, pathogen detection methods, and application areas across global aquaculture operations producing more than 6 million metric tons of shrimp annually. This Shrimp Disease Diagnostics Market Research Report includes segmentation by technology such as PCR, immunoassays, and biosensors, with PCR-based diagnostics accounting for over 60% of total usage due to detection accuracy exceeding 95%. The report evaluates Shrimp Disease Diagnostics Market Size across applications including farm-level testing, hatchery monitoring, and laboratory analysis, supporting deployment across more than 1 million aquaculture facilities worldwide.

The Shrimp Disease Diagnostics Industry Report further analyzes performance metrics such as detection sensitivity below 10 pathogen copies per sample, processing capacity exceeding 100 samples per day for advanced systems, and operational efficiency improvements of up to 40% compared to manual testing methods. Shrimp Disease Diagnostics Market Analysis highlights that more than 65% of demand originates from large-scale commercial farms, while nearly 25% is driven by hatcheries managing over 10 billion shrimp larvae annually.

Shrimp Disease Diagnostics Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 240.36 Million in 2026
Market Size Value By	USD 698.19 Million by 2035
Growth Rate	CAGR of 12.58% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : WSSV (White Spot Syndrome Virus) TSV (Taura Syndrome Virus) YHV/GAV (Yellow Head/Gill Associated Virus) IHHNV (Infectious Hypodermal and Hematopoietic Virus) HPV (Hepatopancreatic Parvovirus) EMS (Early Mortality Syndrome) EHP (Enterocytozoon hepatopenaei) Others By Application : Fisheries Aquaculture Laboratories Marine Laboratories Education and Research Institutes Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample